Business
Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease
$5 million tranche received under up to $20 million financing agreementIND submitted to FDA and HREC approval obtained in Australia; global trial initiation in Q4 2025 HUNTSVILLE, AL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the drawdown of the first $5 million tranche from its previously announced financing agreement, w
About this update from Serina Therapeutics, Inc.
[{"type":"image","alt":"Serina Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Serina Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/f5ef3cecb8662785323a6a370007d6d1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vVhesNODR8eRh4qa0Kn9PQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f5ef3cecb8662785323a6a370007d6d1","width":300,"height":84}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"$5 million tranche received under up to $20 million financing agreement","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"IND submitted to FDA and HREC approval obtained in Australia; global trial initiation in Q4 2025","length":96,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":167,"olType":false},{"type":"text","content":"HUNTSVILLE, AL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the drawdown of the first $5 million tranche from its previously announced financing agreement, which provides up to $20 million in funding upon achievement of defined development milestones. Proceeds will be used to advance the Company’s planned registrational trial of SER-252 for the treatment of advanced Parkinson’s disease.","length":564,"tagName":"p"},{"type":"text","content":"The initial tranche was received in accordance with the terms of the agreement. Subsequent tranches are tied to achievement of defined development milestones, including patient enrollment in the planned clinical trial.","length":218,"tagName":"p"},{"type":"text","content":"“The financing milestone provides the resources to advance SER-252 into the planned registrational trial, marking an important step toward addressing the unmet needs of those with advanced Parkinson’s disease,”, said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “We are pleased to have filed the IND and to be progressing on schedule toward initiating the study in the current quarter.”","length":403,"tagName":"p"},{"type":"text","content":"Serina has submitted an Investigational New Drug (IND) application to the U.S. Food and Dru...